Interius Biotherapeutics
Ben rejoined Bain Capital in 2018 as a Principal in Life Sciences. He initially joined Bain Capital in 2012 as an Associate on the North America Private Equity team, focused on Healthcare.
From 2014 to 2017, Ben was a Vice President at Paulson & Co., focused on public and private equity investments in Healthcare. From 2017 to 2018, he was a Partner at Soleus Capital, an investment firm focused on public and private equity investments in Life Sciences. Prior to initially joining Bain Capital, Mr. Lund was an Analyst in the Healthcare Investment Banking group at Goldman Sachs.
Ben graduated with Phi Beta Kappa distinction from Princeton University with an AB in Molecular Biology and Neuroscience.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Interius Biotherapeutics
1 followers
Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.